Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ginkgo Bioworks Holdings (DNA)
NYSE:DNA
Holding DNA?
Track your performance easily
DNA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.26 - $74.00
Previous Close$10.08
Volume3.32M
Average Volume (3M)1.19M
Market Cap
$579.39M
Enterprise Value$408.77M
Total Cash (Recent Filing)$616.21M
Total Debt (Recent Filing)$445.59M
Price to Earnings (P/E)―
Beta3.23
Next Earnings
Feb 27, 2025EPS Estimate
-$1.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.90
Shares Outstanding57,478,905
10 Day Avg. Volume1,560,760
30 Day Avg. Volume1,192,427
Standard Deviation0.23
R-Squared0.08
Alpha-0.08
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.73
Price to Sales (P/S)2.66
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.88
Enterprise Value/Gross Profit2.07
Enterprise Value/Ebitda-0.77
Forecast
1Y Price Target
$8.67Price Target Upside-13.99% Downside
Rating ConsensusHold
Number of Analyst Covering3
Ginkgo Bioworks Holdings News
PremiumCompany Announcements
Ginkgo Bioworks Reports Q3 Growth and Strategic Deals
PremiumCompany Announcements
Ginkgo Bioworks Reports 61% Revenue Jump in Q3 2024Bulls Say, Bears Say
Bulls Say
Cost ManagementRestructuring efforts are significantly ahead of schedule, with potential for further cost savings beyond the $200 million target by mid-2025.
Financial PerformanceGinkgo's strong cash position with $730 million on its balance sheet provides a solid foundation for future growth and investment opportunities.
Strategic ExpansionThe successful launch of Ginkgo's third new AI asset signals the company's effective execution on expanding its AI infrastructure and tools service franchise.
Bears Say
Financial PerformanceCell Engineering revenue was $30M, which represents a 20% decline compared to the previous year, falling short of market expectations.
Growth ConcernsThe focus on cash and profitability over restructuring may negatively impact top-line growth in the near term.
Investment OutlookAnalyst maintains a Sell rating on Ginkgo shares, seeking more clarity on the success of its cell engineering program monetization.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DNA FAQ
What was Ginkgo Bioworks Holdings’s price range in the past 12 months?
Ginkgo Bioworks Holdings lowest stock price was $5.26 and its highest was $74.00 in the past 12 months.
What is Ginkgo Bioworks Holdings’s market cap?
Currently, no data Available
When is Ginkgo Bioworks Holdings’s upcoming earnings report date?
Ginkgo Bioworks Holdings’s upcoming earnings report date is Feb 27, 2025 which is in 67 days.
How were Ginkgo Bioworks Holdings’s earnings last quarter?
Ginkgo Bioworks Holdings released its earnings results on Nov 12, 2024. The company reported -$1.08 earnings per share for the quarter, beating the consensus estimate of -$2.728 by $1.648.
Is Ginkgo Bioworks Holdings overvalued?
According to Wall Street analysts Ginkgo Bioworks Holdings’s price is currently Overvalued.
Does Ginkgo Bioworks Holdings pay dividends?
Ginkgo Bioworks Holdings does not currently pay dividends.
What is Ginkgo Bioworks Holdings’s EPS estimate?
Ginkgo Bioworks Holdings’s EPS estimate is -$1.5.
How many shares outstanding does Ginkgo Bioworks Holdings have?
Ginkgo Bioworks Holdings has 45,199,330 shares outstanding.
What happened to Ginkgo Bioworks Holdings’s price movement after its last earnings report?
Ginkgo Bioworks Holdings reported an EPS of -$1.08 in its last earnings report, beating expectations of -$2.728. Following the earnings report the stock price went up 2.503%.
Which hedge fund is a major shareholder of Ginkgo Bioworks Holdings?
Among the largest hedge funds holding Ginkgo Bioworks Holdings’s share is Viking Global Investors LP. It holds Ginkgo Bioworks Holdings’s shares valued at 29M.
---
Ginkgo Bioworks Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$8.67 (-13.99% Downside)
$8.67 (-13.99% Downside)
Blogger Sentiment
Neutral
DNA Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 758.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.17%
12-Months-Change
Fundamentals
Return on Equity
-63.51%
Trailing 12-Months
Asset Growth
-26.92%
Trailing 12-Months
Company Description
Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings (NYSE:DNA) is a biotechnology company that offers a platform for cell programming that enables the biological production of various products across the food, pharmaceutical, and fragrance industry. Its platform provides equipment, software, robotic automation, and tools to support genetic engineering, analytics, and fermentation.
---
DNA Company Deck
---
DNA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Ginkgo Bioworks is making strong progress in cost management and achieving technical milestones with major customers, despite facing challenges in revenue from cell engineering and biosecurity. The company maintains a robust cash position and is ahead of schedule in cost-cutting targets. However, declines in certain revenue streams and the impact of one-off costs on cash burn present challenges. Overall, the company is on a positive trajectory towards breakeven.Read More>---
DNA Revenue Breakdown
57.08% Cell Engineering
42.92% Biosecurity
---
DNA Stock 12 Month Forecast
Average Price Target
$8.67
▼(-13.99% Downside)
Technical Analysis
Twist Bioscience
―
Sorrento Therapeutics
―
Intellia Therapeutics
―
Sangamo Biosciences
―
Best Analysts Covering DNA
1 Year
1 Year Success Rate
5/6 ratings generated profit
1 Year Average Return
+49.23%
reiterated a sell rating 4 months ago
Copying Matthew Sykes's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +49.23% per trade.
---